Table 2.
Summary of study cohort clinical characteristics
| Case No | age | LDH | DF Duration | No organs | Organs involved | TV (cc) | RECIST |
|---|---|---|---|---|---|---|---|
| 1 | 36 | NA | 1512 | 1 | Lymph nodes (LN) | 1.93 | SD |
| 2 | 41 | NA | 237 | 5 | LN, lung, soft tissues, bowel, liver | 1065.58 | SD |
| 3 | 58 | 266 | 252 | 3 | Liver, bone, lung | 40.39 | PR |
| 4 | 66 | 226 | 1765 | 1 | lung | 0.3 | PR |
| 5 | 67 | 363 | 109 | 2 | LN, liver | 74.2 | PD |
| 6 | 28 | 193 | 126 | 2 | LN,liver | 14.06 | PD |
| 7 | 46 | 484 | 125 | 3 | Lung, liver, LN | 445.4 | PD |
| 6 | 65 | 251 | 637 | 1 | lung | 5.61 | PR |
| 5 | 50 | 292 | 1586 | 2 | Lung, liver | 7.62 | PD |
| 10 | 81 | 548 | 956 | 3 | s/c tissues, thoracic LN, intra-abdominal deposits | 304.48 | PD |
ECOG European Cooperative Oncology Group, IQR interquartile range, LDH lactate dehydrogenase, LN lymph nodes, PR partial remission, PD progressive disease, RECIST response criteria in solid tumors, S/C subcutaneous, SD standard deviation, TV tumor volume